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The synthesis and purification of radiolabelled immunoconjugates, composed of a human IgM mon- 
oclonal antibody directed against an int~cellular tumour-as~ciated antigen and either poly ( CY-L&I- 
tamic acid) (PGA) or poly [ N5-( 2-hydroxyethyl)-L-~utamine] (PHEG) is described. Coupling of 
polymers to the antibody was performed through disulfide bond formation involving a single thiol 
group at the C-terminus of the polymer chain and 2-pyridyldisullide groups introduced onto the anti- 
body. The antibody was iodinated with 13’1 before conjugation. The polymers contained tyrosinamide 
in a low degree of substitution and were radiolabelled with 12% ‘2SI-labelled PGA and PHEG were 
found to be stable for at least 3 days in murine and human plasma. The bio~st~bution in mice of the 
doubly labelled immunoconjugates was studied and was compared with the pharmacokinetics of the 
individual components. 
PHEG showed a relatively slow blood clearance, the half-life being approximately 10 h with low 
uptake in liver, kidneys and spleen. PGA was rapidly cleared from the circulation and was significantly 
taken up in liver, kidneys and spleen. The biodist~bution of both immunoconju~tes was indistin- 
guishable from that of the IgM proper, with plasma half-lives of approximately 6h, indicating that the 
pharmacokinetic properties of the immunoconjugates are largely determined by the antibody part. 
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Poly (a-r.glutamic acid) 
Introduction 
The targeting of drugs, radioisotopes and tox- 
ins with the aid of monoclonal antibodies 
( MoAbs ) directed against tumor-associated 
antigens is an intensively studied strategy in the 
treatment of cancer [ l-3 1. The vast majority of 
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antibodies employed in clinical investigations are 
MoAbs of murine origin. Most studies in which 
repetitive administration of immunoconjugates 
of these MoAbs was applied were hampered by 
the development of a human anti-mouse anti- 
body {HAMA) response [ 11. Recently, large 
quantities of human MoAbs have become avail- 
able through immunisation of cancer patients 
with autologous tumour cells (active specific im- 
munotherapy, ASI) and subsequent immortalis- 
ation of their peripheral blood l~phoc~es 
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[ 4,5 1. They can be administered to humans in 
gram amounts without evoking an immune re- 
sponse or other undesirable side effects [ 4,5 1. A 
human IgM resulting from this AS1 programme 
designated as 16.88 is being studied extensively 
as a targeting vehicle in radio- and chemo-im- 
munotherapy [ 4,5 1. It reacts with an intracellu- 
lar tumour-associated antigen with an apparent 
molecular mass of 1 O3 kDa on high performance 
size-exclusion chromatography (HP-SEC ) and 
around 40 kDa on polyacrylamide gel electro- 
phoresis in the presence of sodium dodecylsul- 
phonate (SDS-PAGE) [ 61. MoAbs to intracell- 
ular antigens like IgM 16.88 home to necrotic 
areas in the tumour, which results in excellent 
images with y-emitting isotopes [ 41. 
From a theoretical point of view large amounts 
of chemo-immunoconjugates with a molar drug/ 
antibody ratio of at least 50 are needed for an 
effective tumour regression in case ADR is used 
as the cytostatic drug of choice [ 11. Since anti- 
bodies of the IgM type are extremely susceptible 
to chemical substitution, the use of intermediate 
drug carriers is a prerequisite in order to achieve 
the appropriate drug load of the immunoconju- 
gate without affecting solubility and immuno- 
reactivity of the targeting vehicle [ 1,7]. In the 
literature various macromolecular compounds 
have been investigated for application as inter- 
mediate drug carrier, viz. natural proteins like 
serum albumin, polysaccharides and synthetic 
polymers like poly (cu-L-glutamic acid), PGA 
[ 3,7 1. PGA is biodegradable, non-immunogenic 
and non-toxic [ 8,9] and it allows the binding of 
drugs via enzymatically or hydrolytically labile 
bonds [ 3,10-141. Until now, no data on the 
biodistribution of PGA and immunoconjugates 
of this polymer were available. The pharmaco- 
kinetic properties of PGA may be completely de- 
termined by its polyanionic character, which may 
result in a preferential uptake by RES organs as 
was observed for the polycarboxylic acid pre- 
pared from the copolymer of divinylether and 
maleic anhydride (pyran copolymer) [ 15 1. If the 
pharmacokinetic behaviour of the PGA mole- 
cule has a major impact on the biodistribution of 
its immunoconjugate, it will make PGA less suit- 
able as intermediate drug carrier. In that case, the 
uncharged derivative poly [ N5- (2-hydroxy- 
ethyl)-L-glutamine], PHEG [ 14,16,17], may be 
a better alternative. 
In this paper the preparation and fractiona- 
tion of PGA and PHEG and immunoconjugates 
of these polymers with the human MoAb 16.88 
are described. The biodistribution in mice of im- 
munoconjugates consisting of ‘251-labelled poly- 
mers and ’ 31 I-labelled antibody was investigated 
and was compared with the pharmacokinetics of 
the parent components. The implication of the 
results on the use of PGA and PHEG as inter- 
mediate drug carriers in passive immunotherapy 
will be discussed. 
Materials 
THF and dioxane were refluxed overnight and 
distilled in the presence of sodium wire and ben- 
zophenone as an indicator. This procedure was 
repeated until development of a dark-blue color, 
indicating the absence of water. DMF was dis- 
tilled in vacua and used immediately. N-ethyl- 
morpholine and triethylamine were distilled from 
KOH. TFA was distilled. 
The following compounds were obtained from 
the manufacturer indicated and were used as 
supplied. 2-aminoethanol, Merck, F.R.G.; ani- 
sole, Merck, F.R.G.; CDI, Merck, F.R.G.; DTT, 
Merck, F.R.G.; EEDQ, Serva, F.R.G.; ME, 
Merck, F.R.G.; MSA, Merck, F.R.G.; SPDP, 
Pierce, U.S.A.; TPS, Pharmacia, Sweden; tri- 
phosgene, Janssen, Belgium; TyrNH,, Serva, 
F.R.G. 
BLG was prepared as described [ 181. Cys- 
tamine free base was prepared from the dihy- 
drochloride (Janssen, Belgium) as described 
1191. 
Buffers were prepared from analytical grade 
salts, filtered and deaerated with nitrogen. Buffer 
I, 0.10 M NaCl, 0.10 M sodium phosphate, pH 
7.5; buffer II, 0.14 M NaCl, 0.05 M Tris-HCl, pH 
8.0; buffer III, 0.10 M Tris-HCl, 1 mM EDTA, 
pH 8.5; buffer IV, 0.01 M sodium phosphate, 1 
mM EDTA, pH 7.5; buffer V, 0.10 M sodium 
phosphate, 1 mM EDTA, pH 6.0; buffer VI, 0.10 
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M sodium phosphate, 1 mM EDTA, pH 7.0; 
buffer VII, 0.40 M sodium phosphate, 1 mM 
EDTA, pH 7.5. 
Methods 
Analytical procedures 
‘H NMR spectra were recorded on a Bruker 
WP 80 ( 80 MHz). TLC was performed on silica 
coated on plastic sheets 60 F254 (Merck, F.R.G. ) 
using the solvent systems chloroform/metha= 
nol/acetic acid (85/10/5; v/v) or n-butanol/ 
acetic acid/water (4/ l/ 1; v/v). Spots were vis- 
ualized under UV-light or by spraying with nin- 
hydrin solution (Merck, F.R.G.) followed by 
heating for 5-l 0 min at 110°C for detection of 
amino groups, 
The content of PDT groups in polymeric con- 
jugates, PDT-activated proteins and TPS was 
calculated from the increase in absorbance at 343 
nm due to release of 2-pyridinethione upon re- 
duction of the compound in buffer VI with 5- 15 
mM DTT for l-2 h at room temperature using a 
molar absorbance coefficient of 8080 M- ’ *cm- ’ 
[20 J. IgM concentrations were calculated from 
the absorbance at 280 nm using an absorbance 
value of 1.4 for a I mg/ml solution. For IgM 
containing bound PDT groups the absorbance at 
280 nm was corrected for the contribution of the 
PDT group using a molar absorbance coefficient 
of 5 100 M-‘*cm-‘. 
Characterization f polymeric arriers 
Molecular weights of PBLG (M,, M,) were 
dete~ined by HP-SEC/LALLS using DMF as 
the eluent at a flow rate of 1 .O ml/min. The HP- 
SEC unit, consisting of a Waters model 6000A 
pump and a Waters U6K injector, was con- 
nected to three Waters PStyragel ( 105, 1 04, 1 O3 
A) columns (7.8 x 300 mm) in series. The col- 
umn eluate was monitored by a Chromatix 
KMX-6 LALLS apparatus and a Waters R 4 10 
differential refractometer. Refractive index in- 
crements (d&de) at 633 nm were dete~ined 
using a modified Brice-Phoenix BP-ZOO~V dif- 
ferential refractometer. The dnfdc value of 
PBLG in DMF was 0.1113 ml/g. 
The average molecular weight of PGA (M,) 
was determined by intrinsic viscosity measure- 
ments in 0.19 M NaCl, 10 mM sodium phos- 
phate, pH 7.3, using an Ubbelohde capillary di- 
lution viscometer or capillary micro-viscometer 
at 25 “C. The PGA molecular weight was calcu- 
lated from the intrinsic viscosity [q ] and the re- 
lation [q] =4.1 x lo-‘X [M,]0-94 1211. 
The amount of residual benzylester groups in 
PGA was determined from the UV spectra of so- 
lutions of PGA sodium salt in water using molar 
absorbance coefficients of 290 M-’ -cm-’ at 267 
nm [lo]. 
The content of tyrosinamide in polymeric 
conjugates was calculated from the absorbance 
at 275 nm in 0.1 M sodium phosphate buffer, pH 
7.0, using a molar absorbance coefficient of 1400 
M- ’ cm-’ and from the absorbance at 287 nm 
in the same buffer adjusted to pH 12 with 1 M 
NaOH using a molar absorbance coefficient of 
1900 M- ’ *cm- I. Corrections were made for the 
contribution of polymer-bound PDT groups by 
using PDT-PGA and PGA prepared by triethyl- 
amine-initiated polymerization of BLG NCA 
f 101 as controls. The values of the tyrosinamide 
content determined at either 275 or 287 nm were 
identical. 
The content of polymer-bound PDT groups is 
expressed as pmol/g. 
Polyacrylamide gel electrophoresis (PAGE) 
SDS-PAGE was performed in a V16 vertical 
gel electrophoresis system (BRL, U.S.A.). Pro- 
teins were separated in a linear gradient gel 
(T=4-26%, C=3%) with a spacer (T=3%, 
C= 3%) using the discontinuous buffer system 
of Laemmli [22]. The thickness of the gel was 
1.5 mm. Electrophoresis was carried out for 13- 
15 h at 15 mA at ambient temperature. After 
electrophoresis, gels were fixed by immersion in 
a solution of trichloroacetic acid ( 120 g/l) for 
90 min at ambient emperature and were subse- 
quently stained for 24 h by immersion in a solu- 
tion containing Serva Blue G-250 f 1 g/l ), am= 
monium sulfate (60 g/l> and phosphors acid 
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(20 ml/l). The gels were then soaked for 24 h in 
aqueous methanol (250 ml/l) in order to re- 
move excess dye sol particles. The protein-dye 
complexes were fixed in a solution of ammo- 
nium sulfate ( 50 g/l), 
Western blot of SDS-polyacrylamide gels 
Proteins were transferred from the gel onto 
Immobilon@ membranes by electrophoresis in a 
Transblot cell (Biorad, USA) using 25 mM Tris- 
HCl, 0.192 M glycine, 200 ml/l methanol, 300 
mg/l SDS as transfer buffer. Blotting was carried 
out for 2 h at 10 V/cm and 0.25 A at ambient 
temperature, the membrane being placed at the 
anodal side of the gel. After electroblotting the 
individual lanes were cut out and were fraction- 
ated as indicated in Fig. 8. Counting of mem- 
brane species was carried out with a y-counter 
(Packard 5530). 
Synthetic procedures 
BLG NCA 
Syntheses of N-carboxyanhydrides were per- 
formed in a hood. Phosgene present in solutions 
to be discarded was decomposed by adding con- 
centrated ammonia. The reaction was per- 
formed in a 1 1 pear-shaped flask supplied with a 
reflux condenser and a drying tube containing 
CaCl,. Triphosgene [23] (10.0 g, 38.0 mmol) 
was added to a suspension of BLG (20.5 g, 86.4 
mmol) in THF (200 ml) under vigorous stirring 
at room temperature. The mixture was subse- 
quently stirred for 1 h at 5 5 ‘C. The resulting clear 
lightly yellow solution was evaporated to dryness 
in vacua. The yellow oil was dissolved in THF 
(200 ml) and hexanes (mixed isomers; 330 ml) 
were added gradually with stirring until the on- 
set of crystallization. The mixture was then kept 
in the freezer (-18 "C ) overnight. The white 
crystals were isolated by filtration and were 
washed with hexanes, maintaining an atmo- 
sphere of nitrogen. The product was recrystal- 
lized twice from THF/hexanes ( 100 ml/ 120 ml) 
in the same manner and was finally dried in a 
stream of nitrogen. Yield 14.0 g (62%) of BLG 
NCA,m.p. 90-91.5”C (96-97°C [22]). 
Bis-PGA-cystamine 
A solution of cystamine-free base (0.123 g, 
0.79 mmol, ratio monomer/initiator 48 mole/ 
mole) in dioxane ( 12.9 ml) was added with stir- 
ring to a solution of BLG NCA (10.0 g, 38.0 
mmol) in dioxane (240 ml). After 24 h, a sam- 
ple (0.25 g) was taken and the amount of BLG 
NCA was determined by titration with sodium 
methoxide in methanol using thymol blue as the 
indicator [ 241 indicating 95% conversion of the 
monomer. The viscous solution was poured into 
ethanol (4 1) with vigorous stirring. The precip- 
itate was isolated by filtration, washed with 
ethanol and dried in vacua at room temperature 
using KOH pellets as a drying agent to give 7.0 g 
(84%) of a mixture of PBLG and bis-PBLG-cys- 
tamine [ 3 1. 
The crude polymer (6.7 g, 30.6 mmol) was 
dissolved in a mixture of anisole (9.8 ml) and 
TFA (54 ml) with stirring. After 1 h the solution 
was placed in an ice bath and MSA (54 ml) was 
added. The mixture was stirred for 20 min at 0” C 
and for 25 min at 20’ C. The solution was poured 
into diisopropylether (1.2 1) with stirring. The 
white precipitate was isolated by filtration, 
washed with diisopropylether and dried by suc- 
tion. The product was dissolved in water (250 
ml) by adding NaHCOj (2.5 g) and Na,HPO, 
(5 g) until pH 7.5. The solution was filtered 
(0.45 pm, Millipore type HA) and was dialyzed 
exhaustively against water. The solution was ly- 
ophilized yielding 3.68 g (79.4%) of a mixture 
of bis-PGA cystamine, sodium salt, and PGA, 
sodium salt. The ‘H NMR spectrum in D20 was 
consistent with the structure. The amount of re- 
sidual benzyl groups was 0.3 mole % as deter- 
mined by UV spectroscopy. 
PD T-PGA 
Nitrogen was bubbled through a solution of bis- 
PGA-cystamine, sodium salt, ( 1.80 g) in buffer 
III ( 105 ml) for 15 min. DTT (0.272 g, 1.8 
mmol) was added and the solution was stirred 
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for 2 h at 45°C. After cooling to room tempera- 
ture the solution was acidified to pH 2 by the ad- 
dition of 6 N HCl. The suspension of the gel pre- 
cipitate was centrifuged ( 3000 rpm, 10 min ) and 
the clear supernatant was discarded. The gel pre- 
cipitate was resuspended in 0.01 M HCl (3 x 70 
ml ) and water ( 3 x 70 ml ) each time followed by 
centrifugation. The gel precipitate was dissolved 
in water (60 ml) with stirring by adding 
Na2HP0, (2.1 g ) and NaOH to adjust the pH to 
8.0, maintaining an atmosphere of nitrogen. The 
pH of the solution was then adjusted to 6.0 and 
TPS (80 ml in buffer V) was added. The mix- 
ture was left to stand for 2 days at room temper- 
ature. The TPS gel was transferred to a glass fil- 
ter and the gel was washed successively with 
buffer V (5x200 ml), buffer IV (5 x200 ml) 
and buffer III (5 x 200 ml). The filtrates ob- 
tained were each acidified to pH 2.0 with 6 N 
HCI yielding a gel precipitate for both the buffer 
V and buffer IV washings. On acidification of the 
buffer III washings to pH 2, no precipitate was 
formed indicating that all PGA not bound to TPS 
had been removed by the prior washings in buffer 
V and IV. The gel precipitate from the buffer V 
and buffer IV washings was isolated by centrifu- 
gation and was resuspended in 0.01 N HCl 
(3x 100 ml) and water (2x 100 ml) each time 
followed by centrifugation. The suspension of the 
polymer gel in water was finally lyophilized 
yielding 0.45 g (30%) of PGA, H-form. 
Buffer III (90 ml) and 2-mercaptoethanol ( 16 
ml) were added to the TPS gel containing bound 
PGA and the mixture was left to stand for 4 days 
at room temperature. The TPS gel was trans- 
ferred to a glass filter and the gel was washed with 
buffer III ( 5 x 200 ml). The filtrates were com- 
bined and the solution was acidified to pH 2.0 
with 6 N HCI. The polymer precipitate was col- 
lected by centrifugation and was washed several 
times with 0.0 1 N HCl. The polymer precipitate 
was dissolved in a mixture of buffer VII (50 ml) 
and buffer VI ( 50 ml). The polymer solution was 
added slowly to a solution prepared by mixing a 
solution of PDS (570 mg) in ethanol (50 ml) 
with 0.10 M sodium phosphate, pH 7.0 ( 100 ml ) 
and the mixture was stirred for 2 days at room 
temperature. The organic solvent was removed 
by rotary evaporation in vacua and the solution 
was filtered. The clear filtrate was dialyzed ex- 
haustively against water at 4°C. The solution was 
filtered (0.20 pm, Millipore, type HA) and was 
lyophilized yielding 232 mg ( 13W) of PDT-PGA, 
sodium salt. 
D~rivatizat~o~ of PGA and PHEG with 
tyro~~namide 
A solution of PDT-PGA, sodium salt (240 mg, 
1.59 mmol) in water (24 ml) was added drop- 
wise with stirring to 0.1 N HCl (100 ml). The 
mixture was centrifuged (3000 rpm, 10 min) and 
the gel precipitate was resuspended in0.0 1 N HCl 
(2 x 100 ml) and water ( LOO ml ) each time fol- 
lowed by centrifugation. A suspension of the gel 
precipitate in water was lyophilized yielding 
PDT-PGA, H-form ( 164 mg, 80%). 
Derivatization of PGA. To a solution of PDT- 
PGA, H-form, ( 160 mg) in DMF (2 ml) were 
successively added a solution of H-TyrNH* 
(0.025 mmol) in DMF (0.1 ml) and EEDQ 
(0.0297 mmol) in DMF (0.0594 ml). The mix- 
ture was stirred for 2 days at room temperature. 
The resulting gel was dissolved in 0.25 M so- 
dium phosphate buffer, pH 7.3 (20 ml) and lil- 
tered ( 0.45 p ) . The solution was divided in two 
equal parts which were added dropwise with stir- 
ring to 0.1 N HCl ( 100 ml). The gel precipitates 
were washed with 0.01 N WC1 and water fol- 
lowed by centrifugation as described above. 
One batch of the gel precipitate was dissolved 
in 0.25 M sodium phosphate, pH 7.3, and di- 
alyzed against water for 4 days at 4°C. The so- 
lution was filtered (0.45 m, Millipore type HA) 
and was lyophilized yielding PDT-PGA-TyrNH,, 
sodium salt (86.2 mg, 90%). 
Derivatization of PHEG. The other batch of 
the gel precipitate was resuspended inwater ( 100 
ml) and lyophilized yielding PDT-PGA-TyrNH*, 
H-form (77.2 mg, 94%). To a stirred solution of 
this polymer in DMF ( 1.5 ml) were successively 
added saccharin (133 mg, 0.73 mmol) and CDI 
(136 mg, 0.84 mmol). After 30 min 2-aminoe- 
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than01 (0.072 ml, 1.19 mmol) was added. The 
mixture was stirred for 24 h at room tempera- 
ture, mixed with 0.25 M sodium phosphate 
buffer, pH 7.3 (20 ml), acidified with solid so- 
dium dihydrogen phosphate to pH 7.3 and stirred 
for 4 h. After centrifugation of insoluble material 
the solution was dialyzed against 3% NaCl (3 
days) and water (3 days) at 4°C. The solution 
was filtered (0.45 ,um, Millipore type HA) and 
lyophilized yielding PDT-PHEG-TyrNH2 (76.3 
mg, 73%). Amino acid analysis after acidic hy- 
drolysis: Glu, 1 .OO; 2-aminoethanol, 1.08; Tyr, 
0.0 16; peptide content 80%. 
Fractionation ofPGA and PHEG derivatives by 
SEC. Both tyrosinamide-substituted polymers 
were fractionated by gel filtration on a TSK 
Fraktogel HW-55s column (95 x 2.6 cm; 500 ml) 
equilibrated in 0.1 M NaCl, 10 mM sodium 
phosphate, pH 7.0. PDT-PGA-TyrNH2 was dis- 
solved in the equilibration buffer and, prior to 
chromatography, was dialysed against this buffer 
for 24 h with several changes of buffer in order 
to prevent exclusion of the polyelectrolyte from 
the gel due to electrostatic effects. PDT-PHEG- 
TyrNH, was dissolved in the phosphate buffer 
and was applied directly on the column. Elution 
took place at a flow rate of 35 ml/h and the UV 
absorbance of the eluate was monitored at 206 
nm. Fractions of 6 ml were collected and were 
pooled to a ‘high molecular weight’ (HMW) and 
‘low molecular weight’ (LMW) polymer frac- 
tion which were dialyzed against water at 4” C 
and then lyophilized. The separation of the crude 
polymers into fractions of different molecular 
size was confirmed by HP-SEC on a Zorbax GF 
450 column equilibrated in 0.20 M sodium 
phosphate buffer, pH 7.0, at a flow rate of 1.0 
ml/min. The UV absorbance of the eluate was 
monitored at 226 nm or 280 nm. 
Radiolabelling of IgM 16.88 and TyrNH,-substi- 
tuted polymers 
Radio-iodination was carried out following the 
iodogen labelling procedure. Proteins and poly- 
mers were incubated with Na13’I (IgM 16.88) or 
Na’251 (polymers) in vials coated with 500 pg 
iodogen for 30 min at 0’ C. Excess non-bound re- 
agents were removed by gel filtration on pre- 
packed Sephadex G-25 columns (PDlO, Phar- 
macia, Sweden) equilibrated in PBS. 
Plasma stability of ‘251-labelled polymers 
Unfractionated ‘251-labeled carriers PDT-PGA 
and PDT-PHEG were incubated for 1 h at 37 ‘C 
and for various periods of time up to 72 h at 20” C 
in murine plasma. Samples were analyzed by 
GPC on Zorbax GF-450 as described above. 
Fractions of 1 ml were collected and radioactiv- 
ity was measured with a y-counter (Packard 
5530). 
Preparation of doubly labelled immunoconju- 
gates of IgM 16.88 and PGA or PHEG 
A solution of ‘3’I-labelled IgM 16.88 in buffer 
I was reacted with a 200-fold excess of SPDP to 
yield a substitution ratio of 16 PDT groups per 
mole of protein according to Carlsson et al. [ 201, 
‘251-labelled PDT-PGA LMW and PDT-PHEG 
LMW were dissolved in buffer I and were incu- 
bated for 1 h at 37 “C in the presence of DTT (50 
mM) . Excess reducing agents as well as low-mo- 
lecular weight reaction products were removed 
by repeated gel filtration on Sephadex G-25 (PD- 
10) columns equilibrated in buffer I. PDT-acti- 
vated 1311-labelled IgM 16.88 was mixed with the 
thiol-containing ‘251-labelled polymers (5.3 mole 
of polymer thiol groups per mole of protein) and 
the mixtures were reacted for 24 h at ambient 
temperature. Subsequently, the reaction mix- 
tures were applied on a column of TSK Frakto- 
gel HW-55s (75x 5 cm; 1500 ml) equilibrated 
in PBS. Elution took place with PBS as eluent at 
a flow rate of 100 ml/h. The UV absorbance of 
the column eluate was monitored at 280 nm. 
Fractions containing the immunoconjugates were 
pooled and the combined fractions were concen- 
trated to a final protein concentration of around 
3 mg/ml by ultrafiltration on Amicon YM 10. 
The solutions were sterilized by filtration through 
a 0.22 pm (Millex GV, Millipore, U.S.A.) 
membrane. 
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Biodistribution of labeled IgM 16.88, polymers 
and immunoconjugates in mice 
150 ~1 of solutions containing the doubly la- 
belled immunoconjugates or single-labelled par- 
ent compounds at concentrations varying from 
0.6-3 mg/ml of PBS were injected i.v into the 
tail vein of mice followed by injection of 50 ~1 of 
PBS in order to minimize the loss of labelled 
compound by bleeding. Per compound, groups 
of nine mice were used. At 2, 6 and 24 h after 
administration, groups of 3 mice per compound 
were sacrificed. The following tissues were col- 
lected: kidneys, without fat and adrenals; liver 
with gall-bladder; spleen; femur-bone; muscle ti- 
bialis anterior; thyroid together with the sur- 
rounding cartilage. Blood was collected by aorta 
puncture under ether-anaesthesia. Urine was 
collected by bladder punction. Blood, urine and 
tissues except the thyroid were weighed, and ra- 
dioactivity was determined with a well-type Y- 
counter (Packard 5530). The ‘25I activity was 
measured after the decay of the ’ 3 ‘I activity. The 
activity found in blood, urine and tissues is ex- 
pressed as % of the dose administered per gram 
of tissue. For the thyroid the activity is expressed 
as % of the dose administered. 
Results 
Preparation of PGA with terminal thiol groups 
Thiol-PGA was prepared by the method de- 
scribed by Kate et al. [ 3 ] in which the thiol group 
is introduced at the C-terminal polymer end (Fig. 
1, Table 1). A solution of BLG NCA in dioxane 
( 4 wt% ) was polymerized using cystamine as the 
initiator (A/I 48 mole/mole). The polymer 
which was obtained in a yield of 84% is a mix- 
ture of PBLG and bis-PBLG-cystamine [ 3 1. The 
average molecular weights (M,, M,) deter- 
mined by HP-SEC/LALLS using DMF as the 
eluent were 84,600 (M,) and 39,200 (M,) from 
which degrees of polymerization of 386 (DP,) 
and 179 (DP, ), respectively, are calculated. The 
benzyl side chains of the polymer mixture were 
cleaved with methanesulfonic acid/trifluoroac- 
BLG NCA bis-PBLG-cystamide 
1 b-f 
PDT-PGA 
a, Cystamine; b, MSA; c, DTT; d, TPS; B, ME; 1, PDS 
Fig. 1. Preparation of PDT-PGA by polymerization of BLG 
NCA using cystamine as the initiator followed by cleavage of 
benzylester groups and fractionation with TPS. 
etic acid in the presence of anisole to scavenge 
benzyl cations. The mixture of PGA and bis- 
PGA-cystamine thus obtained was isolated in a 
yield of 79% relative to the benzyl-protected 
polymer. The polyacid was treated with DTT to 
reduce polymer-bound disullide groups and thiol- 
PGA was isolated using covalent chromato- 
graphy on TPS. Thiol-PGA was converted to the 
PDT-derivative by treatment with PBS. PDT- 
PGA was obtained in a yield of 13% (batch 1) 
or 17% (batch 2 ) relative to crude PGA (Table 
1). These yields are lower than the yield of 3 1% 
found previously [ 3 1. Analysis of the content of 
PDT groups showed values of 21.2 pmol/g 
(batch 1) and 23.4 pmol/g (batch 2) from which 
M, values of 40300 (DP, 3 12) (batch 1) and 
36300 (DP, 283 ) (batch 2 ) were calculated. 
PGA not bound by TPS was isolated in yields 
of 30% (batch 1) and 5 1% (batch 2 ) . The PDT 
content of the polymer batches was found to be 
6.7-6.8 pmol/g. The presence of PDT groups in 
this PGA fraction indicates that in the disulfide 
exchange between thiol-PGA and Sepharose- 
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TABLE 1 
Preparation of PDT-PGA after polymerization of BLG NCA in dioxane (4 wt%) by cystamine (monomer/initiator ratio 48 
mole/mole) 
Polymer Yield PDT content 
(Oh) (pmol/g) 
104xM, DP, 104xM, DP, Mw/M, 
PBLG + bis-PBLG-cystamine 842 8.465 3865 3.92’ l795 2.16 
PGA + bis-PGA-cystamine’ 79’ 
PGA not bound batch’ 304 6.7 
PGA not bound batch* S14 6.8 4.556 3526 
PDT-PGA batch’ l34 21.2 4.03’ 312’ 
PDT-PGA batch’ 174 23.4 3.63’ 283’ 
‘Amount of residual benzyl groups 0.3 mole %; ‘Relative to BLG NCA; ‘Relative to the total amount of PBLG and bis-PBLG- 
cystamine; 4After fractionation on TPS; relative to the total amount of PGA and bis-PGA-cystamine; ‘By HP-SEC/LALLS in 
DMF, 6By viscosimetry; ‘Apparent value calculated from PDT content. 
TyrNH, -NHCHCONH, 
CHz 
0 
0 
OH 
Rl R2 R3 
PDT-PGA OH (Na) OH (Na) OH (Na) 
PDT-PGA-TyrNH2 OH (Na) TyrNHp R, or RP 
PDT-PHEG-TyrNH2 -NHCH2CH20H TyrNHz R, or Rp 
Fig. 2. Structure of PDT-PGA and of conjugates of PDT-PGA 
or PDT-PHEG and tyrosinamide. 
bound 2-pyridyldithio groups the 2-pyridyl 
moiety is transferred to PGA besides the nor- 
mally expected formation of disulfide-linked 
PGA-Sepharose. 
Preparation and fractionation of TyrNH,-substi- 
toted polymers 
In order to enable labelling of the polymers 
with radioactive iodine, PGA and PHEG were 
substituted to a low degree with TyrNHz (Fig. 2, 
TABLE 2 
Analytical data of conjugates of PGA or PHEG and TyrNH, 
Conjugate Tyr content PDT content 
(mole O/O) (pmol/g) 
PDT-PGA-TyrNH* crude 1.7’ 26.4 
PDT-PGA-TyrNH2 LMW - 23.2 
PDT-PHEG-TyrNH* crude 1.3’, 1.62 22.2 
PDT-PHEG-TyrNH* LMW l.62 15.9 
‘From UV absorbance at 275 nm at pH 7 and at 288 nm at 
pH 12; *From amino acid analysis after acidic hydrolysis. 
Table 2). TyrNH, was linked via the amino 
group with a part of the carboxyl groups of PDT- 
PGA in DMF using EEDQ as the coupling agent 
similar to the procedure developed by us for the 
coupling of ADR and PGA [ lo]. Part of this 
conjugate was reacted with 2-aminoethanol us- 
ing saccharin/CD1 activation in DMF [ lo] to 
fully convert the carboxyl side chains into 2-hy- 
droxyethylamide groups. The TyrNHz content of 
PDT-PGA was 1.7 mol% and that of PDT-PHEG 
was around 1.5 mol%. This level of substitution 
is supposed not to affect the general physico- 
chemical properties of the polymers. Gel liltra- 
tion of the crude PDT-PGA and PDT-PHEG 
preparations of TSK Fraktogel HW-55s re- 
vealed a very broad molecular weight range from 
apparent values of 1.5 x 1 O3 to 60 kDa (Fig. 3 ) . 
In order to facilitate later purification of immu- 
noconjugates of IgM 16.88 from non-conjugated 
PDT.PGA-TYRNH* 
HMW LMW 
l . 
c----l 
HMW LMW 
. . 
! 1 I T I ! 1 
2 4 6 8 10 
ELUTICJN TIME ,h) 
Fig. 3. Preparative SEC on Fractogel TSK HW-5% (90x 2.6 
cm; 500 ml) in 0.10 M NaCl, 10 mM sodium phosphate, pH 
7.0 at a flow rate of 35 ml/h at room temperature. Samples: 
PDT-PGA-TyrNH, and PDT-PHEG-TyrNH,. The fractions 
were pooled as indicated. The elution position of reference 
compounds are (a), Blue Dextran 2000; (b), IgM 16.88; (c), 
fenitin; (d), human IgG, (e), BSA. 
polymers, only those fractions of PGA and 
PHEG with an apparent molecular weight below 
440 kDa (ferritin), designated LMW (Fig. 3), 
were used for immunoconjugation. These LMW 
fractions contained polymers with an apparent 
molecular mass between 760 and 160 kDa 
(PGA) or between 590 and 40 kDa (PHEG) as 
was determined from the midpoints of the elu- 
tion curves obtained by HP-SEC on Zorbax GF 
450 (Fig. 4). The overall yield of PDT-PGA and 
PDT-PHEG after gel filtration on Fraktogel HW- 
55s was excellent; for both polymers a total re- 
covery of over 95% was found. 
Preparation of doubly labelled immunoconjugates 
of IgM 16.88 and PGA or PHEG 
The route of preparation of the immunocon- 
jugate of IgM 16.88 and PHEG is given by way 
of example in Fig. 5. Prior to immunoconjuga- 
tion, IgM 16.88 was labelled with i3’I and the 
LMW fractions of PDT-PGA and PDT-PHEG 
with 1251 using the iodogen procedure. Both the 
antibody and polymers showed identical elution 
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profiles in HP-SEC on Zorbax GF 450 before and 
after radiolabelling indicating that unwanted side 
effects, which may have led to crosslinking, had 
not taken place (data not shown). 13’I-labelled 
IgM 16.88 was reacted with SPDP to yield a PDT 
substitution ratio of 16 moles of PDT per mole 
of antibody. This substitution level has no effect 
on the immunoreactivity of IgM 16.88 (E. Bos 
et al., unpublished results). PDT-activated anti- 
body was added to either of the two ‘251-labelled 
polymers in which thiol groups had been liber- 
ated through incubation with DTT. The immu- 
noconjugates obtained were fractionated by gel 
filtration on TSK Fraktogel HW-55s (Fig. 6). 
Because of their increased molecular weight, the 
immunoconjugates should elute in front of the 
non-conjugated IgM which is eluted between 620 
and 800 ml (Fig. 6 ) and non-conjugated poly- 
mers which should elute between 700 and 1000 
ml, based on the chromatographic behaviour 
presented above. Therefore, the UV-absorbing 
fractions eluting from the TSK Fraktogel HW 
55s column between 520 and 650 ml were pooled 
as indicated (Fig. 6) as they were supposed not 
to contain any of the free parental compounds. 
HP-SEC analysis on Zorbax GF 450 of trial ex- 
periments on immunoconjugate preparations 
(Fig. 7) showed elution profiles of the com- 
pounds very similar to those observed with TSK 
Fraktogel HW 55s. 
The doubly labelled immunoconjugates were 
subjected to SDS-PAGE and Western blotting on 
Immobilon@ membranes (Figs. 8- 11) . Frac- 
tionation and counting of “‘I and ‘25I activity 
revealed, that both labels were present in the first 
two fractions (Figs 9 and 10; cf. Fig. 11) indicat- 
ing that a proper immunoconjugate had been 
formed. Since no 13iI activity could be detected 
in fractions 3 and 4 of the immunoconjugates 
(Fig. 9), it was concluded that these prepara- 
tions were devoid of free IgM. However, in spite 
of careful pooling after gel filtration a substantial 
amount of ‘25I activity (Fig. 10; cf. Fig. 11) was 
found in the lower molecular weight range show- 
ing the presence of non-conjugated PGA and 
PHEG. Possibly, these free polymers were at- 
tached to the antibody or immunoconjugate via 
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A226 
PDT-PGA-TYRNH2 
7.15 
I 
I 
CRUDE L#.4W HMW 
6.60 
0 10 
PDT-PHEG-TYRNH2 
CRUDE 
9.42 
..:_: 
0 10 
LMW 
6.66 
HMW 
ELUTION TIME (min) 
Fig. 4. HP-SEC on Zorbax GF 450 (30x4.6 cm) in 0.20 M sodium phosphate, pH 7.0, at a flow rate of 1.0 mllmin. Samples: 
PDT-PGA-TyrNH* and PDT-PHEG-TyrNH2 before (crude) and after (HMW, LMW) preparative SEC (Fig. 3). 
non-covalent interactions and could not be re- gates but it may well account for up to 35% of 
moved properly under non-denaturing condi- the total ‘25I activity. 
tions. Since we do not know the transfer efti- 
ciency during blotting and the binding efficiency 
of Immobilon membranes for the individual 
compounds it is difficult to estimate the amount 
of free polymer present in the immunoconju- 
Plasma stability of ‘251-labelled PDT-PGA and 
PDT-PHEG 
The stability of unfractionated ‘251-labelled 
PDT-PGA and PDT-PHEG in murine plasma 
IgMw-.NH, 2 IgM 
P 
tHiHc+ NHCH,CH,-S-S-CH,CH,CONH IgM H* m 
;3 
g!CONH, 
8 
2 
0 
H 
a, SPDP; b, HSPHEG-TyrNH, 
Fig. 5. Preparation of immunoconjugates of IgM 16.88 and 
TyrNH,-containing thiol-PHEG. 
was analyzed by HP-SEC on a Zorbax GF 450 
column. As is shown in Fig. 12, no significant 
shift of radioactivity towards the low molecular 
weight area was observed for incubation periods 
up to 72 h, indicating that both polymers were 
stable for that period of time. 
Thus, the biodistribution studies of PGA and 
PHEG and the immunoconjugates will not be 
complicated by biodegradation of the polymers 
and a concomitant change in pharmacokinetic 
behaviour. 
Biodistribution of antibody, polymers and 
immunoconjugates in mice 
From the data presented in Fig. 13, a striking 
difference between the pharmacokinetic behav- 
iour of PGA and its uncharged derivative PHEG 
can be observed. PGA was cleared rapidly from 
the circulation at a t1,2B of less than 2 h and was 
taken up by liver and spleen to an appreciable 
extent, while its metabolisation results in a high 
accumulation of radiolabel in kidneys and secre- 
tion in urine on short term and an elevated up- 
take of iodide in the thyroid gland after 24 h. The 
blood clearance of PHEG was much slower than 
was found for PGA, the t,,28 being approxi- 
mately 10 h, which was attended by a substan- 
A280 
Fig. 6. Preparative SEC on Fractogel TSK HW-55s (75 X 5 
cm; 1500 ml) in buffer I at a flow rate of 100 ml/h. Samples: 
reaction mixtures from ‘3’I-labelled IgM 16.88 and ‘*?-la- 
belled thiol-PGA LMW or thiol-PHEG LMW. The fractions 
( 12.5 ml each) were pooled as indicated. The elution pattern 
of IgM 16.88 is shown for comparison. 
tially lower uptake of the polymer in RES organs. 
From the results it is concluded that the poly- 
anionic character of PGA has a major impact on 
the biodistribution of the molecule and leads to 
a high uptake in liver and spleen as was pre- 
dicted from the results obtained with pyran co- 
polymer [ 15 1. 
As can be seen in Fig. 14, the biodistribution 
of both immunoconjugates, which was derived 
only from the 1311 label on the antibody, is not 
affected by the polymer moiety as it is almost in- 
distinguishable from that of the non-conjugated 
antibody. Antibody and immunoconjugates are 
cleared from the circulation at a relatively high 
rate, the t1,28 being around 6 h, and are accu- 
. . 
IgM 16.66-PGA 
i 
IgM 16.66-PHEG 
h 
I \ 
I \ 
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IgM 16.66 
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Fig. 7. HP-SEC on Zorbax GF 450 (30x4.6 cm) in 0.20 M sodium phosphate, pH 7.0, at a flow rate of 1.0 ml/min. Samples: 
immunoconjugates of IgM 16.88 and thiol-PGA-TyrNH2 LMW or thiol-PHEG-TyrNH, LMW, IgM 16.88 and free polymers. 
Upper part: the arrows indicate the positions of IgM and free polymer, respectively. 
mulating in an early phase in liver and spleen, 
Also in this case, the high uptake in thyroid after 
24 h reflects the dehalogenation and metabolis- 
ation of the compounds injected. Since no differ- 
ence in spleen uptake between free IgM and con- 
jugates is observed, we may conclude that the 
immunoconjugates are devoid of large amounts 
of aggregates. The data on half-life in the circu- 
lation correspond quite well with previously 
published results where IgM 16.88 was adminis- 
tered to nude mice bearing tumour xenografts 
[51. 
Discussion 
Monoclonal antibodies directed to tumour-as- 
sociated antigens have been found to accumulate 
in tumours when administered in human pa- 
tients [ 43 1. This phenomenon allows in vivo di- 
agnosis with the aid of y-emitting isotopes at- 
tached to these antibodies and creates a 
possibility for targeted therapy with (x- or /3- 
emitting isotopes or cytostatic compounds 
[ 1,2,4,5,25 I. 
For optimal efficacy of these so-called radio- 
immunoconjugates and chemo-immunoconju- 
gates an adequate biodistribution that allows a 
specific and high tumour uptake, an appropriate 
residence time of conjugates at the tumour site 
allowing the delivery of sufficient radiation dose 
or the release of sufficient drug, and the possibil- 
ity of repeated administration are of major im- 
portance. The human MoAb IgM 16.88 shows 
potential for targeted therapy on the basis of its 
properties including the extent of tumour locali- 
zation and the enhanced residence time at the 
tumour [ 4 1. Due to binding of this antibody to 
necrotic areas in the tumour [ 41, we aim at the 
use of toxic compounds with a field effect, e.g. P- 
emitting isotopes or drugs bound to the antibody 
through acid-labile linkers where the drug is re- 
kD 
94 
67 
43 
30 
18 
14 
a b R 
Fig. 8. SDS-PAGE of ‘3’I-labelled IgM 16.88 (a), of doubly 
labelled conjugate of IgM 16.88 and PHEG (b) and of ref- 
erence proteins (R). The proteins were stained by Serva Blue 
G-250. “‘1 or “‘1 activity offractions 1-12 (left) in Western 
blots was counted (Figs. 9- 11) 
leased at the tumour site rather than on or in the 
tumour cell. 
In order to deliver a therapeutically effective 
dose of cytostatic drugs at the tumour with the 
set of human MoAbs available, we are obliged to 
use an intermediate drug carrier for which PGA 
and the neutral derivative PHEG were possible 
candidates. In order to test the applicability of 
these polymers in targeted drug therapy immu- 
noconjugates of human IgM 16.88 and PGA or 
PHEG were synthesized and purified and were 
subjected to a biodistribution study. 
PGA and PHEG are degradable by proteolytic 
enzymes [ 26-301. The rate of enzyme-mediated 
main chain cleavage of PGA is low at pH 7-8 and 
is maximal at pH 5 [25,26]. This has been cor- 
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related with the pH-dependent equilibrium be- 
tween the unordered conformation of PGA when 
anionically charged and the a-helical conforma- 
tion of PGA in the acid form with a pH midpoint 
of 5 [ 26,271. PHEG is degradable by various en- 
zymes at neutral pH [ 28-301. For the use of these 
polymers as drug carriers in immunoconjugates, 
it is essential that cleavage of the main chain does 
not occur in the circulation and that the polymer 
remains intact for a reasonable time at the tu- 
mour. The data presented here indicate that the 
size distribution of PGA and PHEG is unaltered 
after incubation in murine plasma for periods up 
to 72 h and that the amount of low molecular 
weight material does not exceed a few percent. 
So, it is concluded that the polymers either free 
or bound to IgM 16.88 remain stable after i.v. 
administration in mice during the period of the 
biodistribution experiments. 
Since the broad size distribution of the poly- 
mers hampered purification of immunoconju- 
gates by SEC, LMW fractions of which the elu- 
tion started at about the same volume as that of 
free IgM, were used as starting material for im- 
munoconjugation. The observation that poly- 
mers with a molecular mass below 50 kDa have 
an apparent molecular weight in the order of 320 
kDa (/3-galactosidase) in SEC, can be explained 
by the fact that PGA and PHEG are randomly 
coiled polymers in aqueous solution [ 3 1,321. 
This implies that the volume occupied by the 
polymer chains may be similar to that of high- 
molecular weight proteins which are relatively 
compact due to secondary and tertiary structures. 
In spite of the fact that the elution profiles of 
the immunoconjugates suggested a complete 
separation from free antibody and polymer, SDS- 
PAGE demonstrated the presence of significant 
amounts of free polymers indicating that a non- 
covalent interaction of polymer and immuno- 
conjugate had taken place during the coupling 
reaction. So, the removal of residual polymer by 
SEC may be improved by elution under slightly 
denaturing conditions which do not affect the 
immunoreactivity of the antibody. 
The presence of the free polymers, however, 
prevented us from analysing the in vivo stability 
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Fig. 9. 13’1 scans of Western blot obtained after SDS-PAGE of ‘311-labelled IgM 16.88 and of doubly labelled conjugates of IgM 
16.88 and PGA or PHEG. 
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Fig. 10. lz51 scans of Western blot obtained after SDS-PAGE 
of doubly labelled conjugates of IgM 16.88 and PGA or 
PHEG. 
of the disulfide bonds between polymer and an- served a reduction of the disuhide bond in an 
tibody by measuring changes in 13’1/‘251 ratio immunotoxin for this reason [ 33 1. They intro- 
with time. The instability of disuhide bridges in duced SMPT as a linker for the conjugation of 
vivo was brought up by Thorpe et al., who ob- antibodies and ricin A, leading to a sterically 
0.4 PGA 
80 
60 
PHEG 
0 
I 2 3 4 5 6 7 8 9 101112 
Fig. 11. lzsI scans of Western blot obtained after SDS-PAGE 
of L2s1-labelled PGA or PHEG. 
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Fig. 12. HP-SEC on Zorbax GF 450 (30 x 4.6 cm) in 0.20 M sodium phosphate, pH 7.0, at a flow rate of 1 .O ml/min. Samples: 
‘251-labelled PDT-PGA and PDT-PHEG (both unfractionated) after incubation in murine plasma for the time periods indicated 
at 20°C or 37°C. 
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Fig. 13. Distribution of lzsI bound to PGA or PHEG in mice. 
hindered disulfide bridge between IgG and the 
toxin moiety. At any rate, the absence of free IgM 
allowed us to study biodistribution of IgM-poly- 
mer conjugates through the 13iI label of the 
antibody. 
The similarity in biodistribution of immuno- 
conjugates and free IgM as described in this pa- 
per may look surprising in view of the pharma- 
cokinetic properties of free PGA and PHEG 
which were shown to be quite different. How- 
ever, it has to be kept in mind that the polymers 
account for only lo- 15% of the total mass in im- 
munoconjugates assuming an average of three 
polymer chains per antibody molecule, a num- 
ber that is usually found for immunoconjugates 
of IgM and HSA at a comparable PDT-substitu- 
tion of the antibody (E. Bos et al., unpublished 
results ). 
An important conclusion can be drawn, i.e. 
that the antibody molecule is the major deter- 
minant in the process of biodistribution. From 
1000 1 c 
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t 
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$ 
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Fig. 14. Distribution of 13’1 bound to IgM 16.88 and conjugates of IgM 16.88 and PGA or PHEG in mice. 
this point of view, PGA as well as PHEG may be 
used as intermediate drug carriers in immuno- 
conjugates. Since the attachment of the highly 
charged PGA molecule to an antibody was found 
to have a major impact on the physicochemical 
properties of the immunoconjugate in spite of its 
minor ~ont~bution to the mass, it might be ad- 
vantageous touse PHEG as carrier instead, as the 
uncharged character of this derivative may be less 
dominant over those of the antibody, thus facil- 
itating purification methods other than SEC, e.g. 
ion-exchange chromatography or hydrophobic 
interaction chromato~aphy. 
At present we focus on the synthesis and puri- 
fication of immunoconjugates using PHEG as 
carrier and adriamycin as cytostatic drug which 
is coupled to the polymer via acid-labile bonds. 
Conclusions 
( 1) The biodistribution of IgM 16.88 and im- 
munoconjugates of IgM 16.88 with either PGA 
or PHEG are similar. ( 2 ) Both PGA and PHEG 
seem useful as drug carrier in immunoconju- 
gates. ( 3 ) Removal of unbound polymers from 
immunoconjugates i difficult probably due to 
complex formation between polymers and im- 
munoconjugates. (4) PHEG seems promising as 
a carrier for release of drug in the circulation due 
to high blood levels, slow clearance and low RES 
uptake. 
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Abbreviations 
ADR, adriamy~in; ASI, active specific immu- 
notherapy; BLG, y-benzyl+glutamate; BSA, bo- 
vine serum albumin; CDI, N,N’-carbonyldiimi- 
dazole; DMF, N,~-dimethylfo~amide; DTT, 
dithiothreitol; EDTA, ethylene diamine tetraa- 
cetate; EEDQ, IV-ethoxycarbonyl-2-ethoxy-1,2- 
dihydroquinoline; HP-SEC, high-performance 
size exclusion chromatography; HSA, human 
serum albumin; LALLS, low-angle light scatter- 
ing; M,, number-average molecular weight; M,, 
weight-average molecular weight; ME, 2-mer- 
captoethanol; MoAb, monoclonal antibody; 
MSA, methanesulphonic acid; NCA, N-carbox- 
yanhydride; PBLG, poly (~-ben~l-L-~uta- 
mate); bis-PBLG-cystamine, N,N’-bis [ poly ( y- 
benzyl-L-glutamyl) cystamine; PBS, phos- 
phate-buffered saline; PDS, 2,2’-dipyridyldisul- 
fide; PDT, 2-pyridyldithio; PDT-PGA, 2-( 2- 
pyridyldithio)-~- [poly (a-~- 
glutamyl ) ] ethylamine; PGA, poly ( a-r_-gluta- 
mate); bisPGA-cystamine, N&V -bis [ poly ( QI-L- 
glutamyl ) lcystamine; PHEG, poly [ NS- (2-hy- 
droxyethyl)-L-glutamine]; RES, reticulo-en- 
dothelial system; SDS-PAGE, polyacrylamide gel 
electrophoresis n the presence of sodium dode- 
cylsulphonate; SEC, size exclusion chromato- 
graphy; SMPT, 4-succinimidyloxycarbonyl-cr- 
methyl-a! (2-pyridyldithio) toluene; SPDP, N- 
succinimidyl 3- (2-pyridyldithio)propionate; 
TFA, trifluoroacetic acid; TLC, thin-layer chro- 
mato~aphy; TPS, Thiopropyl Sepharose 68; 
TyrNH2, tyrosinamide. 
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